You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 10,286,029


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,286,029
Title:Method for treating HCV
Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.
Inventor(s): Awni; Walid M. (Green Oaks, IL), Bernstein; Barry M. (Mequon, WI), Campbell; Andrew L. (Lake Forest, IL), Dutta; Sandeep (Lincolnshire, IL), Lin; Chih-Wei (Vernon Hills, IL), Liu; Wei (Mundelein, IL), Menon; Rajeev M. (Buffalo Grove, IL), Podsadecki; Thomas J. (Chicago, IL), Wang; Tianli (Lake Bluff, IL), Mensing; Sven (Mannheim, DE)
Assignee: AbbVie Inc. (North Chicago, IL)
Application Number:14/676,370
Patent Claims: 1. A method for treatment of a patient infected with hepatitis C virus (HCV), comprising administering at least two direct acting antiviral agents (DAAs) to said patient, wherein said treatment does not include administration of either interferon or ribavirin to said patient, and said treatment lasts for 8, 9, 10, 11 or 12 weeks, and wherein said at least two DAAs comprise (1) Compound 1 ##STR00008## or a pharmaceutically acceptable salt thereof and (2) Compound 2 ##STR00009## or a pharmaceutically acceptable salt thereof.

2. The method of claim 1, wherein said treatment lasts for 12 weeks.

3. The method of claim 1, wherein said treatment lasts for 10 weeks.

4. The method of claim 1, wherein said treatment lasts for 8 weeks.

5. The method of claim 1, wherein said patient is infected with HCV genotype 1.

6. The method of claim 1, wherein said patient is infected with HCV genotype 2.

7. The method of claim 1, wherein said patient is infected with HCV genotype 3.

8. The method of claim 1, wherein said patient is without cirrhosis.

9. The method of claim 1, wherein said patient is with compensated cirrhosis.

10. The method of claim 1, wherein said patient is a treatment-naive patient.

11. The method of claim 1, wherein said patient is a treatment-experienced patient.

12. The method of claim 1, wherein said at least two DAAs consist of (1) Compound 1 or a pharmaceutically acceptable salt thereof and (2) Compound 2 or a pharmaceutically acceptable salt thereof.

13. The method of claim 12, wherein said treatment lasts for 12 weeks.

14. The method of claim 12, wherein said treatment lasts for 8 weeks.

15. The method of claim 12, wherein said patient is infected with HCV genotype 1.

16. The method of claim 12, wherein said patient is infected with HCV genotype 2.

17. The method of claim 12, wherein said patient is infected with HCV genotype 3.

18. The method of claim 12, wherein said patient is a treatment-naive patient without cirrhosis.

19. The method of claim 12, wherein said patient is a treatment-naive patient with compensated cirrhosis.

20. The method of claim 12, wherein said patient is a treatment-experienced patient without cirrhosis.

21. The method of claim 12, wherein said patient is a treatment-experienced patient with compensated cirrhosis.

22. The method of claim 12, wherein said at least two DAAs consist of Compound 1 and Compound 2, and wherein Compound 1 is administered once daily to said patient, and Compound 2 is administered 120 mg once daily to said patient.

23. The method of claim 22, wherein said patient is infected with HCV genotype 1.

24. The method of claim 22, wherein said patient is infected with HCV genotype 2.

25. The method of claim 22, wherein said patient is infected with HCV genotype 3.

26. The method of claim 22, wherein said patient is infected with HCV genotype 4.

27. The method of claim 22, wherein said patient is infected with HCV genotype 5.

28. The method of claim 22, wherein said patient is infected with HCV genotype 6.

29. A method for treatment of a patient infected with HCV, comprising administering at least two direct acting antiviral agents (DAAs) to said patient, wherein said treatment does not include administration of either interferon or ribavirin to said patient, and said treatment lasts for 16 weeks, and wherein said at least two DAAs comprise (1) Compound 1 or a pharmaceutically acceptable salt thereof and (2) Compound 2 or a pharmaceutically acceptable salt thereof.

30. The method of claim 29, wherein said at least two DAAs consist of Compound 1 and Compound 2 each of which is administered to said patient once daily.

31. The method of claim 30, wherein said Compound 2 is administered 120 mg once daily to said patient.

32. The method of claim 31, wherein said patient is without cirrhosis.

33. The method of claim 31, wherein said patient is with compensated cirrhosis.

34. The method of claim 31, wherein said patient is a treatment-experienced patient.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.